NCT02226952View on ClinicalTrials.gov

Antiviral Efficacy, Pharmacokinetics and Safety of BILN 2061 ZW in Patients With Chronic Hepatitis C Virus Infection

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

November 30, 2001

Primary Completion Date

April 30, 2002

Conditions
Hepatitis C, Chronic
Interventions
DRUG

BILN 2061 W, low dose

DRUG

BILN 2061 W, medium dose

DRUG

BILN 2061 W, high dose

DRUG

Placebo

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY